• Seres Therapeutics plans to pursue continued development of SER-155 for immune checkpoint inhibitor-related enterocolitis, based on early investigator-sponsored trial results.
• Management is engaging potential partners, including companies with immune checkpoint inhibitor franchises, to evaluate next steps for the irEC program.
• The company is seeking funding from collaborators and financing partners to advance a Phase 2 study of SER-155 in allogeneic hematopoietic cell transplantation.
• Development planning also targets expansion of its live biotherapeutics platform into broader inflammatory and immune diseases, including ulcerative colitis and Crohn's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-298005), on July 08, 2026, and is solely responsible for the information contained therein.